Precision BioSciences Holds Annual Stockholder Meeting

The latest announcement is out from Precision BioSciences ( (DTIL) ).

On May 28, 2025, Precision BioSciences, Inc. held its annual meeting of stockholders, where 71% of the common stock was represented. The meeting resulted in the election of Kevin J. Buehler and Shari Lisa Piré as Class III directors, and the approval of several proposals, including the ratification of Deloitte & Touche LLP as the independent accounting firm and an annual advisory vote on executive compensation. However, a proposal to amend the Certificate of Incorporation regarding officer exculpation did not pass as it failed to meet the required voting threshold.

The most recent analyst rating on (DTIL) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.

Spark’s Take on DTIL Stock

According to Spark, TipRanks’ AI Analyst, DTIL is a Neutral.

The overall stock score reflects the balance of promising revenue growth and strategic advancements in clinical programs against the backdrop of profitability and cash flow challenges. The attractive valuation and low debt levels provide a foundation for potential long-term growth, though significant improvements in cash management and profitability are necessary to enhance the stock’s outlook.

To see Spark’s full report on DTIL stock, click here.

More about Precision BioSciences

Average Trading Volume: 138,092

Technical Sentiment Signal: Sell

Current Market Cap: $55.88M

See more data about DTIL stock on TipRanks’ Stock Analysis page.